Thus, while the preponderance of evidence supports elevated expression of FOXC1 being an accurate predictor of adverse clinical outcomes, the two notable exceptions include ovarian cancer and Luminal B molecular subtype of breast cancer where elevated expression of FOXC1 predicts good prognosis. Here, FOXC1 is linked to breast carcinoma.